Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
about
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaNovel agents in the treatment of multiple myeloma: a review about the futureThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveThe role of maintenance therapy in multiple myelomaMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.The next generation of novel therapies for the management of relapsed multiple myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaPhase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Immunotherapy in hematologic malignancies: past, present, and future.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Carfilzomib boosted combination therapy for relapsed multiple myelomaPotent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Novel investigational drugs active as single agents in multiple myeloma.Immunologic approaches for the treatment of multiple myeloma.Which therapies will move to the front line for multiple myeloma?Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016.The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.An update on the role of daratumumab in the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.The safety of daratumumab for the treatment of multiple myeloma.A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
P2860
Q26745919-6275852C-1211-4527-8045-1BC613E5CF78Q26745924-DAF93AAA-E1C3-46E4-8AC4-A6BB5756673BQ28069789-21E979BE-23F0-464E-87F4-4B89C00F1B84Q28071644-A70C4B23-910A-49DD-B317-0928E3476B6AQ28075816-FFBBA016-5C16-458C-85B9-BCD3204814DFQ30238893-CB0A5438-CA09-4616-B61D-928390BE5988Q30248534-0B950055-ABB7-439D-BE33-68412F38802EQ30249167-ECA356B1-E66D-442E-9B18-8BE94E5476B8Q31119290-8D39AF63-0DA5-44F0-B327-59594506DA21Q33432492-3D3DDB07-CC8C-4161-8DFF-27256B22F7ADQ33434683-49DA56DE-F778-4A86-86D4-1900C64A2558Q33437691-A1CCD9F5-204A-4871-B51D-1A276E3A822FQ33439437-1BC7B732-D6B5-4FE6-B729-DC99D4207193Q33441476-67A919A8-AE77-4694-9F2B-3AF0FD24881CQ33593865-3686EEBE-1681-467B-9743-66C430311E4CQ34551324-40E55AE3-9935-44CC-B23D-568C73C571D8Q34556156-2B88390E-555B-4F7F-AA7F-DCD0F71392FFQ36363958-6E4B35F4-1E73-4DB2-BFC5-1695733A0DE8Q37076421-BCBACB9A-BFE1-4837-9326-C51B851A77B0Q37517482-2C1336BC-981F-4C3C-8647-B7762028F196Q37593573-5D88C256-4027-44B9-B054-63F58640950FQ37652953-114E1B7F-02F7-4FA3-B30A-68CB2D3605E8Q37687119-0B92BC0E-9213-4942-8CD7-FA9BCBE7C375Q37697253-A603D9DB-30A0-4E92-AB2A-BB633168B14EQ37737800-467E0623-BC90-4537-8235-EB85AA32C2A3Q38599023-51A6C3BD-A563-4CBD-9BCA-F301209B032CQ38672091-6720F6BD-D240-45CE-90F8-4B2859B6E4B1Q38690290-17228175-281D-48E6-8493-1FC62492E26AQ38692244-F8DED8DE-F129-4476-9813-67D772E8D1E3Q38733592-D3243723-737E-4FDF-9385-F24DC47E3C80Q38735228-4ACE3E32-D082-4B4F-B8B6-34F5FA82601CQ38745915-EBDBE03B-000F-467F-8ADA-DBE327C0D985Q38775700-2606CCAC-14A8-4289-B5C2-57F17A529F36Q38786149-A089D42A-08AD-46C5-AFC7-1E8253A1B469Q38792725-96F2149E-9C19-4FB6-ABD6-88EB4DF917A8Q38793959-D65CD5BC-12E7-480C-A08E-323B7E71E70CQ38797097-94924CFE-4564-404A-8870-009869560361Q38820002-A0D24654-EB61-4BA8-9FA8-E3C4316051B0Q38824538-F6D93ED8-4455-4788-B73C-D4E9BD54865FQ38853857-057A888F-5843-495D-A8A8-850A6F7768F0
P2860
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@en
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@nl
type
label
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@en
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@nl
prefLabel
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@en
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@nl
P2093
P50
P1433
P1476
Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.
@en
P2093
Ajai Chari
Amitabha Mazumder
Amrita Krishnan
Andrew Belch
Andrzej Jakubowiak
Brendan M Weiss
Clarissa M Uhlar
Darrell White
Don A Stevens
Emma C Scott
P304
P356
10.1016/S0140-6736(15)01120-4
P407
P577
2016-01-06T00:00:00Z